You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020138022
Dec 20203206
Jan 20213006
Feb 20212209
Mar 202152015
Apr 20212806
May 202116015
Jun 2021007
Jul 2021009
Aug 20210013
Sep 20210011
Oct 202130023
Nov 202122013
Dec 20211402
Jan 20221803
Feb 20221802
Mar 2022604
Apr 20223404
May 20224205
Jun 20223606
Jul 20227008
Aug 202250010
Sep 2022112013
Oct 20225607
Nov 202250011
Dec 20222801
Jan 20235403
Feb 20234201
Mar 20234804
Apr 20233606
May 20234404
Jun 20233004
Jul 20232405
Aug 20232603
Sep 20231201
Oct 20233007
Nov 20233003
Dec 20233405
Jan 20241000
Feb 20241801
Mar 20242607
Apr 20241201
May 20241000
Jun 20241800
Jul 20241801
Aug 20242803
Sep 20242001
Oct 20241605
Nov 20242404
Dec 20241202
Jan 2025804
Feb 2025002
Mar 2025008
Apr 2025003
May 2025002
Jun 2025002
Total15340323